- Home
- ONCY vs BENF Comparison
ONCY vs BENF Comparison
Compare ONCY & BENF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCY
- BENF
- Stock Information
- Founded
- ONCY 1998
- BENF 2003
- Country
- ONCY Canada
- BENF United States
- Employees
- ONCY N/A
- BENF N/A
- Industry
- ONCY Pharmaceuticals and Biotechnology
- BENF Blank Checks
- Sector
- ONCY Health Care
- BENF Finance
- Exchange
- ONCY Nasdaq
- BENF Nasdaq
- Market Cap
- ONCY 89.7M
- BENF 91.9M
- IPO Year
- ONCY 1999
- BENF N/A
- Fundamental
- Price
- ONCY $1.02
- BENF $0.51
- Analyst Decision
- ONCY Strong Buy
- BENF
- Analyst Count
- ONCY 5
- BENF 0
- Target Price
- ONCY $5.00
- BENF N/A
- AVG Volume (30 Days)
- ONCY 948.7K
- BENF 27.8M
- Earning Date
- ONCY 11-07-2025
- BENF 11-14-2025
- Dividend Yield
- ONCY N/A
- BENF N/A
- EPS Growth
- ONCY N/A
- BENF N/A
- EPS
- ONCY N/A
- BENF N/A
- Revenue
- ONCY N/A
- BENF N/A
- Revenue This Year
- ONCY N/A
- BENF N/A
- Revenue Next Year
- ONCY N/A
- BENF $22.09
- P/E Ratio
- ONCY N/A
- BENF N/A
- Revenue Growth
- ONCY N/A
- BENF N/A
- 52 Week Low
- ONCY $0.33
- BENF $0.22
- 52 Week High
- ONCY $1.51
- BENF $2.36
- Technical
- Relative Strength Index (RSI)
- ONCY 37.21
- BENF 45.46
- Support Level
- ONCY $0.92
- BENF $0.54
- Resistance Level
- ONCY $1.05
- BENF $0.93
- Average True Range (ATR)
- ONCY 0.08
- BENF 0.17
- MACD
- ONCY -0.02
- BENF -0.04
- Stochastic Oscillator
- ONCY 25.00
- BENF 5.39
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
About BENF Beneficient
Beneficient is a technology-enabled financial services holding company that (together with its subsidiaries) provides simple, rapid, and cost-effective liquidity solutions to participants in the alternative asset industry through its end-to-end online platform, AltAccess. BCG's products and services are designed to meet the unmet needs of mid-to-high net-worth individual investors, small-to-midsize institutional investors, family offices, and fund general partners. Its bespoke liquidity solutions for otherwise illiquid alternative asset investments are delivered through proprietary technology and a financing and trust structure. It has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts.